22.05.2019 CO.DON AG  DE000A1K0227

DGAP-News: CO.DON AG: Capital increase completed successfully


 

DGAP-News: CO.DON AG / Key word(s): Capital Increase
CO.DON AG: Capital increase completed successfully

22.05.2019 / 19:49
The issuer is solely responsible for the content of this announcement.


CO.DON AG - Capital increase completed successfully

Berlin / Teltow, 22 May 2019 - CO.DON Aktiengesellschaft, Berlin (DE000A1K0227) successfully placed its cash capital increase with subscription rights from authorised capital by issuing 1,056,568 new shares today. The gross issue proceeds amount to some EUR 4.3 million.

After entry in the commercial register the company's share capital is therefore increased by EUR 1,056,568.00 from EUR 20,331,382.00 to EUR 21,387,950.00 by the issue of 1,056,568 new bearer shares, each representing EUR 1.00 of the company's share capital.

The new shares are to be admitted for trading on the regulated market (General Standard) of Frankfurt Stock Exchange without a prospectus and are expected to be listed on 24 June 2019.

"My thanks go to our shareholders for their great interest in the capital increase. It is an expression of their confidence in the business case of CO.DON AG and an important acknowledgement of our progress on the way towards marketing our main product across the EU. This funding enables us to step up our European expansion once again and to take the first steps towards extending our portfolio", said Ralf Jakobs, CEO of CO.DON AG.

Lead manager for the cash capital increase was Baader Bank Aktiengesellschaft, Unterschleißheim.

CO.DON AG develops, produces and markets autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated. In July 2017 we received marketing authorisation for the advanced therapy medicinal product Spherox from the European Medicines Agency. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.
Further information is available from www.codon.de

Investor Relations and Press Contact:
Matthias Meißner, M.A.
Corporate communications / IR / PR
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309
Email: ir@codon.de



22.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CO.DON AG
Warthestraße 21
14513 Teltow
Germany
Phone: 03328 43460
Fax: 03328 434643
E-mail: info@codon.de
Internet: www.codon.de
ISIN: DE000A1K0227
WKN: A1K022
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 814881

 
End of News DGAP News Service

814881  22.05.2019 

fncls.ssp?fn=show_t_gif&application_id=814881&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 2,69 3,62 4,48 5,09 5,60 5,96 5,65 8,80
EBITDA1,2 -2,24 -2,50 -2,27 -2,61 -3,41 -6,73 -7,84 0,00
EBITDA-Marge3 -83,27 -69,06 -50,67 -51,28 -60,89 -112,92 -138,76 0,00
EBIT1,4 -2,38 -2,68 -2,48 -2,86 -3,65 -6,98 -8,56 0,00
EBIT-Marge5 -88,48 -74,03 -55,36 -56,19 -65,18 -117,11 -151,50 0,00
Jahresüberschuss1 -2,38 -2,68 -2,49 -2,87 -3,65 -7,05 -6,27 0,00
Netto-Marge6 -88,48 -74,03 -55,58 -56,39 -65,18 -118,29 -110,97 0,00
Cashflow1,7 -2,33 -1,56 -1,78 -2,97 -3,62 -5,88 -8,14 0,00
Ergebnis je Aktie8 -0,22 -0,24 -0,18 -0.18 -0,21 -0,36 -0,55 -0,74
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
co.don
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A1K022 2,040 49,56
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,000 -6,58
KBV KCV KUV EV/EBITDA
2,92 - 8,77 -5,016
Dividende '18 in € Dividende '19e in € Div.-Rendite '18
in %
Hauptversammlung
0,00 0,00 0,00 12.06.2019
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.08.2019 30.04.2019
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-25,38% -45,32% -35,75% -53,10%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu CO.DON AG  ISIN: DE000A1K0227 können Sie bei DGAP abrufen

Biotechnologie , A1K022 , CNWK , XETR:CNWK